A Heavy Metal Baseline Score Predicts Outcome in Acute Myeloid Leukemia
-
2020/04/01
-
Details
-
Personal Author:Albarede F ; Carson A ; Cortes J ; Dumontet C ; Kanagal-Shamanna R ; Kornblau S ; Matera E-L ; Ohanian M ; Plesa A ; Ruvolo P ; Telouk P ; Tidwell RSS
-
Description:Despite abundant epidemiological data linking metals to leukemia and other cancers, baseline values of toxic and essential metals in patients with leukemia and the clinical impact of these metals remain unknown. Thus, we sought to quantify metal values in untreated patients with acute myeloid leukemia (AML) and controls and determine the impact of metal values on AML patients' survival. Serum samples from patients with untreated AML and controls at Hospices Civils de Lyon were analyzed and compared for trace metals and copper isotopic abundance ratios with inductively coupled plasma mass spectrometry. Survival analysis was performed as a function of metal values, and a multi-metal score was developed for patients with AML. Serum samples were collected from 67 patients with untreated AML and 94 controls. Most patients had intermediate-risk cytogenetics (63.1%) without FLT3 internal tandem duplication mutations (75.6%) or NPM1 mutations (68.1%). Most metal values differed significantly between AML and control groups. Patients with lower magnesium and higher cadmium values had the worst survival rates, with only 36% surviving at 6 months (P = .001). The adverse prognostic effect of this combination was maintained on multivariate analysis. Based on this, we developed a novel metal score, which accounts for multiple relative abnormalities in the values of five toxic and five essential metals. Patients with a higher metal score had significantly worse survival, which was maintained on multivariate analysis (P = .03). This baseline metal scoring system was also prognostic when we applied it to a separate population of front-line AML patients. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:0361-8609
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Pages in Document:422-434
-
Volume:95
-
Issue:4
-
NIOSHTIC Number:nn:20059887
-
Citation:Am J Hematol 2020 Apr; 95(4):422-434
-
Contact Point Address:Maro Ohanian, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0428, Houston, TX 77030
-
Email:mohanian@mdanderson.org
-
Federal Fiscal Year:2020
-
NORA Priority Area:
-
Performing Organization:University of Texas Health Science Center, Houston
-
Peer Reviewed:True
-
Start Date:20050701
-
Source Full Name:American Journal of Hematology
-
End Date:20250630
-
Collection(s):
-
Main Document Checksum:urn:sha-512:3ce76bb01c5d28f62c6906013129a8c89ca2ab2dca870ad241fcfa51e48a990db063112e6ad04250c96016e7486373b73e12ab334379b27ac8c4747fd8a82bc1
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like